John Cope, MD
Internal Medicine · Demorest, GANPI 1609878974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Novo Nordisk at 39.0% of the total.
Across 236 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Bayer$388
- Sanofi-aventis U.S. LLC$355
- AstraZeneca$295
- Lilly USA, LLC$206
- Pfizer$182
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,592100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,797 |
| Bayer | 17 | $388 |
| Sanofi-aventis U.S. LLC | 17 | $355 |
| AstraZeneca | 17 | $295 |
| Lilly USA, LLC | 13 | $206 |
| Pfizer | 10 | $182 |
| AbbVie | 9 | $178 |
| Boehringer Ingelheim | 10 | $172 |
| Amarin Pharma, Inc. | 6 | $104 |
| Medtronic | 1 | $100 |
| GSK | 5 | $93 |
| Abbott | 5 | $87 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Exact Sciences | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 6 | $59 |
| Antares Pharma, Inc. | 3 | $53 |
| Corcept Therapeutics | 2 | $45 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Merck | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Seqirus USA Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$238
- Xultophy 100/3.6$119
- Kerendia$109
- RYBELSUS$108
How this compares
$4,612 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $197,932 |
| OzempicSemaglutide | 117 | $165,029 |
| MounjaroTirzepatide | 115 | $155,853 |
| FarxigaDapagliflozin Propanediol | 122 | $125,938 |
| JardianceEmpagliflozin | 74 | $90,167 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 53 | $72,037 |
| XareltoRivaroxaban | 82 | $67,695 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 216 | $65,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $47,631 |
| JanuviaSitagliptin Phosphate | 52 | $46,384 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $45,805 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $35,843 |
| ProliaDenosumab | 19 | $32,838 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $31,596 |
| RybelsusSemaglutide | 11 | $23,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $1,797 | $234,060153 claims |
| PfizerEliquis | $182 | $197,932205 claims |
| Lilly USA, LLCMounjaro | $206 | $155,853115 claims |
| GSKArexvy, Trelegy Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta | $93 | $142,745352 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $295 | $142,639163 claims |
| Boehringer IngelheimJardiance | $172 | $90,16774 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $355 | $72,03753 claims |
| MerckJanuvia, Lagevrio (Eua) | $30 | $60,90574 claims |
| AmgenProlia | $13 | $32,83819 claims |
| BayerKerendia | $388 | $13,56021 claims |
| AbbVieSynthroid | $178 | $7,806106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Demorest
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.